Corvus Pharmaceuticals announces initiation of phase 1/1b clinical trial
Corvus announced it is enrolling patients in a multicenter Phase 1/1b clinical trial of CPI-006, a humanized monoclonal antibody directed against CD73. The three-arm study in patients with a variety of solid tumors is evaluating CPI-006 administered as a single agent, in combination with CPI-444. April 26, 2018